McKesson announced plans to spin-off its Med-Surgical Unit. This contributed 18% of Operating Profit last year. For the Quarter, revenue was a miss $90.8bn vs $94bn expected but EBIT $1.56bn was +25% yoy and 3% ahead of expectations.
• Full Year saw Adj Earnings of $4.234bn +15% yoy with Q4 $1.274bn +57%
• Full Year Revenues $327.7bn +18%.
• Most of McKesson’s revenue is attributable to the US Pharma sector which only has 1.19% margins. Med-Surg has 9%; Prescription Tech 17%; International 2.7%.
• Prescription Tech could be said to have more synergies with the main Pharma prescription business; Med-Surg less so.
Find more articles and bullets on these widgets:
The trend condition in Gold remains bullish and the latest pull back appears corrective. Moving average studies are unchanged, they remain in a bull-mode position highlighting a dominant uptrend. Price has traded through support at the 20-day EMA. The next key support to watch lies at 2946.9, the 50-day EMA. A resumption of gains would refocus attention on $3196.2, a Fibonacci projection. The bull trigger is 3167.8, the Apr 3 high.
Brent futures continue to trade in a volatile manner and the contract has again traded to fresh cycle lows, today. Recent weakness has resulted in a move through both the 20- and 50-day EMAs and a number of important support levels have been cleared. This signals scope for a continuation, and sights are on $58.85 next, a Fibonacci projection. On the upside, initial firm resistance is seen at $67.95, the Mar 5 low.